Literature DB >> 11383067

[Resection of colorectal liver metastases. What prognostic factors determine patient selection?].

J Scheele1, A Altendorf-Hofmann, T Grube, W Hohenberger, R Stangl, K Schmidt.   

Abstract

AIM OF THE STUDY: Based on a consecutive series of patients undergoing liver resection for colorectal metastases, indicators of prognosis and selection criteria were evaluated. PATIENTS AND METHODS: From 1960 to 1998, a total of 654 patients underwent resection of colorectal liver metastases. In 516 patients (78.9%) this was an R0 resection for initial metastatic disease. These patients form the basis for the investigation.
RESULTS: 30-day mortality in this group was 5.8%, while the total procedure-related mortality was 8.3%. Significant morbidity was observed in 16% of patients. Follow-up information until 1 January, 2000 was achieved in 99.5% of patients. Including operative mortality, the actuarial 5-, 10-, and 20-year survival is 38 +/- 5%, 27 +/- 6% und 24 +/- 24%, rising to 41 +/- 5%, 29 +/- 6% and 26 +/- 26% after excluding operative deaths. Tumor-free survival is 35 +/- 5% at 5 years. In the multivariate analysis the following factors are associated with decreased crude survival: extrahepatic tumor (P < 0.0001), intraoperative hypotension (P = 0.0001), non-anatomical procedures (P = 0.0002), a metastasis diameter > or = 5 cm (P = 0.0002), unfavourable grading of the primary tumor (P = 0.0003), satellite metastases (P = 0.0069), mesenteric lymph node involvement (P = 0.0260), use of FFP (P = 0.0307) and synchronous diagnosis of metastases (P = 0.1240). With respect to disease-free survival metastasis diameter is first, followed by extrahepatic disease (P < 0.0001 each). Satellite metastases are removed, while the primary tumor site becomes important with inferior results for rectal cancer (P = 0.0188). The other factors remain stable and in the same order. The number of independent tumor nodules as well as the width of resection margin fail to be significant in both univariate and multivariate analysis.
CONCLUSION: These results underline the paramount importance of an R0 resection, but diminish the relevance of most commonly used "contraindications". For the actual decision on liver resection, beside the possibility of achieving an R0 situation, safety aspects regarding comorbidity and acceptable extent of parenchyma loss represent the prime limitation.

Entities:  

Mesh:

Year:  2001        PMID: 11383067     DOI: 10.1007/s001040051345

Source DB:  PubMed          Journal:  Chirurg        ISSN: 0009-4722            Impact factor:   0.955


  35 in total

Review 1.  The surgical treatment of hepatic metastases in colorectal carcinoma.

Authors:  Ulf Peter Neumann; Daniel Seehofer; Peter Neuhaus
Journal:  Dtsch Arztebl Int       Date:  2010-05-14       Impact factor: 5.594

Review 2.  [Liver metastases. Diagnosis and therapy].

Authors:  R Konopke; H D Saeger
Journal:  Chirurg       Date:  2003-09       Impact factor: 0.955

3.  [Nonoperative ablation for liver metastases. Possibilities and limitations as a curative treatment].

Authors:  C-T Germer; H J Buhr; C Isbert
Journal:  Chirurg       Date:  2005-06       Impact factor: 0.955

4.  Contrast-enhanced ultrasonography to detect liver metastases : a prospective trial to compare transcutaneous unenhanced and contrast-enhanced ultrasonography in patients undergoing laparotomy.

Authors:  R Konopke; S Kersting; H Bergert; A Bloomenthal; J Gastmeier; H D Saeger; A Bunk
Journal:  Int J Colorectal Dis       Date:  2006-05-30       Impact factor: 2.571

5.  Patient selection for hepatic resection for metastatic colorectal cancer.

Authors:  Matthew J Weiss; Michael I D'Angelica
Journal:  J Gastrointest Oncol       Date:  2012-03

6.  Resection margin with anatomic or nonanatomic hepatectomy for liver metastasis from colorectal cancer.

Authors:  Yoshihiro Inoue; Michihiro Hayashi; Koji Komeda; Shinsuke Masubuchi; Masashi Yamamoto; Hidenori Yamana; Hajime Kayano; Tetsunosuke Shimizu; Mitsuhiro Asakuma; Fumitoshi Hirokawa; Yoshiharu Miyamoto; Atsushi Takeshita; Yuro Shibayama; Kazuhisa Uchiyama
Journal:  J Gastrointest Surg       Date:  2012-02-28       Impact factor: 3.452

7.  [Present state of radio frequency ablation of liver tumors in Germany].

Authors:  M Birth; P Hildebrand; G Dahmen; A Ziegler; D C Bröring; C Hillert; H P Bruch
Journal:  Chirurg       Date:  2004-04       Impact factor: 0.955

8.  [Metastases of colorectal carcinoma].

Authors:  S Clasen; H Rempp; P L Pereira
Journal:  Radiologe       Date:  2008-11       Impact factor: 0.635

9.  Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET).

Authors:  Felix G Fernandez; Jeffrey A Drebin; David C Linehan; Farrokh Dehdashti; Barry A Siegel; Steven M Strasberg
Journal:  Ann Surg       Date:  2004-09       Impact factor: 12.969

10.  Impact of neoadjuvant chemotherapy with FOLFOX/FOLFIRI on disease-free and overall survival of patients with colorectal metastases.

Authors:  Sarah Y Boostrom; David M Nagorney; John H Donohue; Scott Harmsen; Kristine Thomsen; Florencia Que; Michael Kendrick; Kaye M Reid-Lombardo
Journal:  J Gastrointest Surg       Date:  2009-09-16       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.